PATENT CLAIM ANALYSIS

Application Number: 16400227
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["514", "302000"]

Abstract:
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

Claim (Index 13):
A method of treating Prader-Willi syndrome comprising administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof wherein the method provides an in vivo plasma profile comprising a AUC 6-12  of less than about 900 ng\u00b7hr/ml.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 100.0
- Lexical Diversity: 1.40984
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16157653', '15680417', '15961002', '15191068', '15873425']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7827226010249152
- 35 USC 102 Novelty (BERT): 0.5461024412634248
- Combined Prediction Score: 0.7590605850487662
- Mean Citation Score: 367.676682
- Max Citation Score: 409.04376
- Similarity Product: 323.06858388685225

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test